ropinirole IR / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 31 Diseases   4 Trials   4 Trials   380 News 


«123456»
  • ||||||||||  fluoxetine / generics
    Journal:  Experimental manipulation of monoamine levels alters personality in crickets. (Pubmed Central) -  Oct 25, 2019   
    Our results indicate that the serotonergic system explains more variation in personality than manipulations of the dopaminergic system. Additionally, they suggest that monoamine systems differ across taxa, and confirm the importance of the mode of action of pharmaceuticals in determining their effects on behaviour.
  • ||||||||||  rasagiline / Generic Mfg.
    Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease (Agora 3 West, Level 3) -  Sep 24, 2019 - Abstract #MDSCongress2019MDS_591;    
    A case of visual hallucinations, agitation, and myoclonus that appeared with the use of high-dose pramipexole has been reported. Although visual and auditory hallucinations associated with dopamine agonist use have been reported as side effects, olfactory hallucinations have not been reported in the literature.
  • ||||||||||  clozapine / generics
    Factitious Disorder Imposed on Another mimicking a Dopamine Dysregulation Syndrome (Les Muses Terrace, Level 3) -  Sep 24, 2019 - Abstract #MDSCongress2019MDS_347;    
    Physicians should assess and contol patients closely when tapering DAs to prevent this disabling syndrome. She had PD for 12 years, and she was under Carbidopa/L-dopa 250/25mg 4 times daily and Ropinirole 8mg daily, with previous control of her disease...She reduced Carbidopa/L-dopa dosage (600mg daily), suspended the dopaminergic agonist and started Clozapine 25mg daily which prevented further abnormal movements and motor fluctuations...We presented a new type of DDS in PD, without the addictive dimension usually associated to this syndrome which makes therapeutics and prognosis different.
  • ||||||||||  carbamazepine / Generic Mfg.
    TREATMENT OF RESTLESS LEGS SYNDROME AT THE UNIVERSITY OF WASHINGTON (Board #229t - Exhibition) -  Sep 17, 2019 - Abstract #WSS2019WSS_1829;    
    Gabapentinoids were also prescribed in a minority of patients (25.8%). A large proportion of patients were prescribed opioids (62.2%), which may not be the optimal treatment.
  • ||||||||||  ropinirole IR / Generic mfg.
    Trial completion date, Trial primary completion date:  Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole (clinicaltrials.gov) -  Sep 3, 2019   
    P1/2,  N=26, Recruiting, 
    A large proportion of patients were prescribed opioids (62.2%), which may not be the optimal treatment. Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Jul 2020
  • ||||||||||  Ritalin (methylphenidate tablet) / Generic Mfg.
    Journal:  Corneal Edema Associated With Systemic Dopaminergic Agents. (Pubmed Central) -  Aug 25, 2019   
    We believe that these agents are linked with the reversible corneal edema seen in our 3 patients. This strongly correlates with previous studies that have linked amantadine, a drug that blocks dopamine reuptake, to reversible corneal edema.
  • ||||||||||  Trivastal (piribedil) / Servier, Permax (pergolide) / Eli Lilly
    Clinical, Journal:  A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR-G protein interactions. (Pubmed Central) -  May 31, 2019   
    In a D-Gα versus D-Gα screening, we retrieved five agonists that are currently being used in antiparkinsonian medications. We determined that in this assay, piribedil and pergolide are full agonists for the recruitment of Gα but are partial agonists for Gα, that the agonist activity of ropinirole is biased in favor of Gα recruitment, and that the agonist activity of apomorphine is biased for Gα We proposed that this newly developed assay could be used to develop molecules that selectively modulate a particular G protein pathway.
  • ||||||||||  ropinirole IR / Generic mfg.
    Trial completion date, Trial primary completion date:  Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis (clinicaltrials.gov) -  May 15, 2019   
    P4,  N=60, Enrolling by invitation, 
    Further investigation in independent samples is warranted. Trial completion date: Jul 2020 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
  • ||||||||||  ropinirole IR / generics
    Journal:  Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. (Pubmed Central) -  May 13, 2019   
    We further evaluated multiple-phenotype rescue of these subclassified SALS models using agents selected from non-SOD1 FALS models, and identified ropinirole as a potential therapeutic candidate. Integration of the datasets acquired in this study permitted the visualization of molecular pathologies shared across a wide range of SALS models.
  • ||||||||||  pramipexole IR / generics
    Journal:  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease. (Pubmed Central) -  Apr 26, 2019   
    DAs may also be considered as adjunct therapy in older persons when motor symptoms are no longer adequately controlled by levodopa or when motor fluctuations and dyskinesia appear. DAs may be used cautiously in older persons with cognitive impairment and orthostatic hypotension but should be avoided when there is a history or risk of psychosis or impulse control disorders.
  • ||||||||||  methylphenidate tablet / generics, venlafaxine / generics, bromocriptine / generics
    Clinical, Journal:  Takotsubo cardiomyopathy associated with serotonin syndrome in a patient with stroke: A case report. (Pubmed Central) -  Apr 7, 2019   
    Prognosis of TC is usually favorable; however, it could be fatal in some cases. Clinicians should be aware of the potential development of TC in patients with stroke presenting with SS following the administration of serotonergic and dopaminergic agents.
  • ||||||||||  ropinirole IR / Generic mfg., gabapentin / Generic mfg.
    Trial completion date, Trial primary completion date:  DISCO-RLS: DIalysis Symptom COntrol-Restless Legs Syndrome Trial (clinicaltrials.gov) -  Mar 21, 2019   
    P3,  N=80, Not yet recruiting, 
    Clinicians should be aware of the potential development of TC in patients with stroke presenting with SS following the administration of serotonergic and dopaminergic agents. Trial completion date: Feb 2020 --> Aug 2020 | Trial primary completion date: Dec 2019 --> Apr 2019
  • ||||||||||  ropinirole IR / Generic mfg.
    Trial completion date, Trial primary completion date:  Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis (clinicaltrials.gov) -  Jun 13, 2018   
    P4,  N=60, Enrolling by invitation, 
    Phase classification: P4 --> P2 Trial completion date: Mar 2019 --> Jul 2020 | Trial primary completion date: Sep 2018 --> Dec 2019
  • ||||||||||  ropinirole IR / Generic mfg.
    Enrollment change:  Cognitive Remediation for Cocaine Dependence (clinicaltrials.gov) -  Mar 30, 2018   
    P2,  N=119, Completed, 
    Trial completion date: Mar 2019 --> Jul 2020 | Trial primary completion date: Sep 2018 --> Dec 2019 N=200 --> 119
  • ||||||||||  ropinirole IR / Generic mfg.
    Trial completion:  Cognitive Remediation for Cocaine Dependence (clinicaltrials.gov) -  May 3, 2017   
    P2,  N=200, Completed, 
    No longer recruiting --> Completed Recruiting --> Completed
  • ||||||||||  ropinirole IR / Generic mfg.
    Trial completion, Trial initiation date:  Ropinirole in the Treatment of Bipolar Depression (clinicaltrials.gov) -  Apr 18, 2017   
    P4,  N=40, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Initiation date: Feb 2006 --> Sep 2005
  • ||||||||||  ropinirole IR / Generic mfg.
    Trial primary completion date:  Cognitive Remediation for Cocaine Dependence (clinicaltrials.gov) -  Dec 29, 2015   
    P2,  N=200, Recruiting, 
    Recruiting --> Completed | Initiation date: Feb 2006 --> Sep 2005 Trial primary completion date: May 2015 --> Dec 2016